Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein
Introduction
Levetiracetam (2S-(oxo-1-pyrrolidinyl)butanamide, Keppra®) is a novel antiepileptic drug marketed as add-on therapy for partial-onset seizures in adults (Hovinga, 2001).
Levetiracetam has a peculiar pharmacological profile that distinguishes it from all the other antiepileptic drugs. While it affords protection against seizures induced in audiogenic genetically susceptible mice as well as in electrically orpentylenetetrazol induced kindling models, it is devoid of anticonvulsant activity in most acute animal models of epilepsy such as the maximal electroshock model (Klitgaard et al., 1998, Klitgaard, 2001). Its mechanism of action does not involve the classical targets of the other antiepileptic drugs i.e. γ-aminobutyric acid (GABA) facilitation, inhibition of sodium channels or modulation of low-voltage activated calcium channels (Margineanu and Klitgaard, 2002, Rigo et al., 2002). However, a brain specific binding site for levetiracetam, named levetiracetam binding site was described and characterized in rat brain for the first time in 1995 (Noyer et al., 1995) using [3H]levetiracetam as radioligand. The binding of levetiracetam to this site was reversible, saturable and highly stereoselective. The availability of a new, more potent analogue, [3H]ucb 30889 enabled further characterization of these sites using autoradiography (Gillard et al., 2003). Also, irreversible binding of the radioligand under UV irradiation was performed permitting covalent binding and subsequent determination of the molecular weight of the binding site (Fuks et al., 2003). This led to the cloning and the identification of this site as being the SV2A protein (Lynch et al., 2004). The combined observations that SV2A knock-out mice develop lethal seizures soon after birth (Crowder et al., 1999) together with an excellent correlation between the affinity of levetiracetam analogues for SV2A in rat brain or for the recombinant protein and their anticonvulsant potency in audiogenic mice (Noyer et al., 1995, Lynch et al., 2004) strongly support a role of SV2A in the antiepileptic properties of levetiracetam.
The biology of SV2A itself is not entirely elucidated but it has been proposed that SV2 proteins are involved in exocytosis and more particularly, because of their structural analogy with transporters, may play a role in the homeostasis of synaptic vesicle constituents such as ATP or calcium (Bajjalieh et al., 1992, Janz et al., 1999). Impact on calcium homeostasis is further supported by data showing that SV2A interacts with synaptotagmin, a protein considered as a calcium sensor (Schivell et al., 2005) and by the recent publication by Cataldi et al. (2005) showing that levetiracetam inhibits bradykinin- and ATP-induced inositol triphosphate (IP3)-dependent calcium release in PC12 cells, cells that are known to possess SV2A but not in 3T3-fibroblasts where SV2A is absent.
This paper reports an in-depth comparison of the binding properties of the human recombinant SV2A protein expressed in CHO cells with those of the native protein, present in its natural environment, the human brain.
Section snippets
Drugs and radioligand
Levetiracetam (2S-(2-oxo-1-pyrrolidinyl)butanamide), piracetam (2-(2-oxo-1-pyrrolidinyl)acetamide), ucb 30889 ((2S)-2-[4-(3-azidophenyl)-2-oxopyrrolidin-1-yl]butanamide) and analogues were synthesised at UCB (Braine L'Alleud, Belgium). Bemegride, bicuculline, chlordiazepoxide and pentobarbital were purchased from Sigma-Aldrich (Bornem, Belgium). Pentylentetrazol was acquired from Acros Organics (Pittsburgh, USA). [3H]ucb 30889 (32 Ci/mmol) was custom labelled by Amersham Biosciences
Binding kinetics
The binding of [3H]ucb 30889 in human brain and to recombinant SV2A was reversible and displayed both biphasic association and dissociation kinetics as depicted in Fig. 1 and reported in Table 1. The fast component for both association and dissociation had a half-time ranging from 1 to 4 min and represented from 30% to 36% of the sites in association experiments and from 33% to 49% in dissociation experiments. The half-times of the slow component ranged from 20 to 41 min.
The dissociation
Discussion
The antiepileptic drug levetiracetam has been shown to bind to a specific binding site in rat brain (Noyer et al., 1995, Gillard et al., 2003). This binding site has been identified as the SV2A protein, a protein ubiquitously distributed in the central nervous system as a component of synaptic vesicles (Lynch et al., 2004). In our study, we aimed to extend these observations by studying more in depth the binding properties of [3H]ucb 30889 in CHO cells stably expressing the human recombinant
Acknowledgements
The authors wish to thank Mrs. Isabelle Jacques, Mr. Frédéric Aelbrecht and Mr. Michel Legrand for their skilful technical assistance.
We also want to acknowledge Dr Berkley Lynch and Mrs. Dina Anderson for providing us with the CHO clone expressing the human SV2A protein.
References (20)
- et al.
The synaptic vesicle protein SV2 is a novel type of transmembrane transporter
Cell
(1992) - et al.
Localisation and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines
Eur. J. Pharmacol.
(2003) - et al.
Functional interactions between the subunits of the lactose transporter from Streptomyces thermophilius
J. Mol. Biol.
(2005) - et al.
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Eur. J. Pharmacol.
(2003) - et al.
SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release
Neuron
(1999) - et al.
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Eur. J. Pharmacol.
(1998) - et al.
Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes
Life Sci.
(1981) - et al.
The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes
Eur. J. Pharmacol.
(1995) - et al.
G-protein-coupled receptor dimerization: modulation of receptor function
Pharmacol. Ther.
(2001) - et al.
SV2A and SV2C contain a unique synaptotagmin-binding site
Mol. Cell. Neurosci.
(2005)
Cited by (139)
Effect of levetiracetam therapy on electrocardiographic parameters
2023, Archives de PediatrieCitation Excerpt :The heart receives sympathetic and parasympathetic innervation and is also capable of generating action potentials through transmembrane ion currents without external stimulation. Some studies have shown that the binding of levetiracetam to the synaptic vesicle 2A presynaptic vesicle protein can regulate neuronal transmission and neurotransmitter release [21,22]. At the same time, other studies have shown that levetiracetam can also affect the ion channels.
Effect of antiepileptic drug levetiracetam on cochlear function
2022, Hearing ResearchCitation Excerpt :The data indicate that the highest LEV dose of 1000 mg/kg had no or only a slight effect on the OHC function. By binding to the synaptic vesicle protein 2 and inhibiting L-type calcium channel activity (Lynch et al., 2004; Gillard et al., 2006; Yan et al., 2013) LEV may affect neurotransmitter release from the IHCs. Thus, it is expected that LEV would reduce the amplitude of CAP.
Modulation of nociception and pain-evoked neurobehavioral responses by levetiracetam in a craniotomy pain model
2022, Behavioural Brain ResearchThe Epilepsies
2022, Comprehensive PharmacologyDistinct synaptic vesicle recycling in inhibitory nerve terminals is coordinated by SV2A
2020, Progress in NeurobiologyCitation Excerpt :Notably, SV2A expression level is correlated with epilepsy (Tokudome et al., 2016), such that a complete absence of SV2A causes severe epilepsy (Janz et al., 1999). Levetiracetam, an anti-epilepsy drug, exerts its effects by binding to SV2A (Gillard et al., 2006; Loscher et al., 2016). In this study, we explored functional differences between presynaptic terminals of excitatory and inhibitory synapses.